Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis by Dranitsaris G, Shane LG, Crowther M, Feugere G, Woodruff S

Get full text

Assessment of von Willebrand disease as a risk factor for primary postpartum haemorrhage. by Chee, Y, Townend, J, Crowther, M, Smith, N, Watson, H

Assessment of von Willebrand disease as a risk factor for primary postpartum haemorrhage by Chee, Y, Townend, J, Crowther, M, Smith, N, Watson, H

Multivariate generalized linear mixed-effects models for the analysis of clinical trial–based cost-effectiveness data by Achana, F, Gallacher, D, Oppong, R, Kim, S, Petrou, S, Mason, J, Crowther, M

Purification and characterization of endogenous peptides extracted from HLA-DR isolated from the spleen of a patient with rheumatoid arthritis. by Gordon, R, Young, J, Rayner, S, Luke, R, Crowther, M, Wordsworth, P, Bell, J, Hassall, G, Evans, J, Hinchliffe, SA

Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy by Conrado, DJ, Larkindale, J, Berg, A, Hill, M, Burton, J, Abrams, KR, Abresch, RT, Bronson, A, Chapman, D, Crowther, M, Duong, T, Gordish-Dressman, H, Harnisch, L, Henricson, E, Kim, S, McDonald, CM, Schmidt, S, Vong, C, Wang, X, Wong, BL, Yong, F, Romero, K, Duchenne Muscular Dystrophy Regulatory Science Consortium (D-RSC)